5323312022-07-012022-09-305323312022-09-305323312022-03-315323312022-04-012022-09-305323312022-07-012022-09-30in-bse-fin:OtherExpenses1Member5323312022-04-012022-09-30in-bse-fin:OtherExpenses1Member5323312022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312022-07-012022-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15323312022-04-012022-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532331AJANTPHARMNOTLISTEDINE031B01049AJANTA PHARMA LIMITEDEquity2022-04-012023-03-312022-11-032022-10-21INRCroresHalf yearlySingle segmentPHARMACEUTICAL2022-11-0314:00:002022-11-0315:30:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedConsolidated9381000000403500000978450000020540000004083000001352000001861400000990000032700000029587000007754500000203000000002030000000563700000-9970000046400000001566000000000015660000001970000015857000000015857000000257100000212.2212.220012.2212.221. The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 3 November 2022. The statutory auditors have expressed unmodified opinion. The review report has been filed with the stock exchange and is available on company website. <BR> 2. Board of Directors have approved payment of interim dividend on 3 November 2022 of Rs. 7 per equity share of face value of Rs. 2 each. <BR> 3. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. <BR> 4. Pursuant to approval given by its shareholders, the Group has during the quarter ended June 2022, issued 4,27,08,385 equity shares of Rs. 2 each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 2 (Two) existing equity share. Accordingly, the earnings per share has been adjusted for previous periods and presented in accordance with Ind AS 33, Earnings Per Share. <BR> 5. During the quarter Nil equity shares (previous year 4,000 equity shares) of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011 and Share Based Incentive Plan 2019, resulting in an increase in the paid-up share capital by Rs. Nil (previous year Rs. 8,000) and securities premium account by Rs. Nil (previous year Rs. 0.54 crores). <BR> 2022-04-012022-09-30UnauditedConsolidated188903000007311000001962140000040045000007737000006235000003690800000187000006448000005616800000153728000004248600000042486000001018800000-8240000093640000003312200000000033122000007270000033849000000033849000000257100000225.8525.850025.8525.85Other Expenses2958700000Other Expenses561680000013969700000182300000081600000082520000000025100000000121700000372700000830500000905000001799320000074858000002810800000118043000003288100000477000008030000031400000180626000009271000002647550000098000000444785000002571000003577770000036034800000036034800000149000000217500000232400000201600000936200000028400000139860000010000038754000002367800000624330000034670000099400000355700000070451000000084437000004447850000018700000434900000-9674000000435000002800000-120000020450000006031000000-310100000064480000028200000-14600000840000086900000-400000-5775000000147000008000001690000000000207600000445620000000074700000003709200000000175500000016280000000012600000855400000000000000000000000230000006500000-242620000000054000000000042000000820000000-750000000-73300000120970000014800000122450000020636000003288100000Items that will not to be reclassified subsequently to profit or loss-10500000-10500000Items that will not to be reclassified subsequently to profit or loss-9000000-9000000-3600000-3100000Items that will be reclassified subsequently to profit or loss2660000026600000Items that will be reclassified subsequently to profit or loss786000007860000000